ストックスクリーナーアプリを入手
1.48
6.47%
0.09
前日終値:
$1.39
開ける：
$1.4
24時間の取引高:
16,422
Relative Volume:
0.16
時価総額：
$50.16M
収益：
-
当期純損益:
$-13.27M
株価収益率:
-9.0244
EPS:
-0.164
ネットキャッシュフロー:
$-7.70M
1週間 パフォーマンス:
+2.07%
1か月 パフォーマンス:
+30.99%
6か月 パフォーマンス:
+38.97%
1年 パフォーマンス:
-4.52%
1日の値動き範囲:
$1.375
$1.4865
1週間の範囲:
$1.32
$1.4967
52週間の値動き範囲:
$0.8075
$1.74
Okyo Pharma Limited Stock (OKYO) Company Profile
OKYO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
1.48 | 49.21M | 0 | -13.27M | -7.70M | -0.164 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Okyo Pharma Limited (OKYO) 最新ニュース
OKYO Pharma ("OKYO" or the "Company")announces issuance of U.S. Patent No. 11,254,720 covering OKYO’s dry eye drug candidate OK-101 for use to treat ocular neuropathic pain - Barchart.com
OKYO Pharma’s (OKYO) Buy Rating Reaffirmed at HC Wainwright - Defense World
Neuropathic Ocular Pain Market Expected to Experience Major - openPR.com
Neuropathic Ocular Pain Market Expected to Experience Major Growth by 2034, According to DelveInsight | Novartis, OKYO Pharma, AbbVie Inc., Aciex Therapeutics, Novaliq, Oculeve and Allergan, Adverum - Barchart.com
Allergic Conjunctivitis Pipeline 2025: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO Pharma - Barchart.com
OKYO Pharma Limited (NASDAQ:OKYO) Sees Significant Decrease in Short Interest - Defense World
ADS Program collapse - Investegate
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain - marketscreener.com
OKYO moves toward FDA talks after eye drug trial – ICYMI - Proactive financial news
FDA grants fast track to OKYO Pharma’s neuropathic pain drug - Investing.com Australia
Small cap wrap: GoviEx, NextSource Materials, Voyageur Pharmaceuticals, OKYO Pharma... - Proactive financial news
FDA grants fast track to OKYO Pharma’s neuropathic pain drug By Investing.com - Investing.com Nigeria
FDA grants fast track designation to OKYO Pharma’s urcosimod for treatment of neuropathic corneal pain - Ophthalmology Times
OKYO Pharma’s Urcosimod Receives FDA Fast Track Designation for Neuropathic Corneal Pain - TipRanks
FDA Fast-Tracks Novel Eye Pain Drug: OKYO's Urcosimod Targets Untreated Corneal Condition - Stock Titan
OKYO Pharma secures FDA fast-track designation for urcosimod for neuropathic corneal pain - Proactive financial news
OKYO Pharma accelerates neuropathic corneal pain treatment with early closure of Phase 2 trial - Proactive financial news
Market movers: Snap, Super Micro Computer, OKYO Pharma... - Proactive financial news
Okyo Pharma announces plans to accelerate development of urcosimod - TipRanks
OKYO Pharma Accelerates Urcosimod Development for Neuropathic Corneal Pain - TipRanks
OKYO Pharma speeds up NCP drug development - Investing.com
OKYO Pharma Announces Plans to Accelerate the Clinical - GlobeNewswire
OKYO Pharma Limited Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain - marketscreener.com
OKYO Pharma accelerates clinical development of urcosimod for neuropathic corneal pain - Proactive financial news
Press Release Distribution & PR Platform - ACCESS Newswire
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain - ADVFN
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain - ADVFN
Kyverna Therapeutics (NASDAQ:KYTX) and OKYO Pharma (NASDAQ:OKYO) Financial Review - Defense World
OKYO Pharma CEO discusses FDA Fast Track filing for urcosimodICYMI - Proactive financial news
OKYO Pharma achieves key stability milestone for Urcosimod in clinical development - Proactive financial news
OKYO Stock Price and Chart — NASDAQ:OKYO - TradingView
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod - GlobeNewswire
Small cap wrap: OKYO Pharma, Charbone Hydrogen, Hillcrest... - Proactive financial news
OKYO Pharma reports long-term benefits of its neuropathic corneal pain treatment - Seeking Alpha
OKYO Pharma releases positive long-term stability data for urcosimod in neuropathic corneal pain - Ophthalmology Times
Urcosimod shows promise in long-term stability test - Investing.com
OKYO Pharma confirms stability of drug candidate By Investing.com - Investing.com South Africa
Urcosimod shows promise in long-term stability test By Investing.com - Investing.com India
OKYO Pharma Achieves Key Stability Milestone for Urcosimod - TipRanks
OKYO Pharma confirms stability of drug candidate - Investing.com
OKYO Pharma reports long-term shelf stability of corneal pain treatment - Proactive financial news
Dauntless Investment Group, LLC Acquires Significant Stake in OK - GuruFocus
OKYO Pharma (NASDAQ:OKYO) versus IN8bio (NASDAQ:INAB) Head-To-Head Analysis - Defense World
OKYO Pharma Limited (NASDAQ:OKYO) Sees Significant Growth in Short Interest - Defense World
Okyo Pharma Limited Announces Filing of A Patent Application Covering the Use of Chemerin and Associated Analogues to Treat “Cytokine Storm” Associated with COVID-19 and ARDS - marketscreener.com
OKYO Pharma seeks FDA fast track for eye pain treatment By Investing.com - Investing.com Australia
OKYO Pharma seeks FDA Fast Track for eye pain drug By Investing.com - Investing.com Australia
OKYO Pharma seeks FDA fast track for eye pain treatment - Investing.com India
Okyo Pharma Limited (OKYO) 財務データ
収益
当期純利益
現金流量
EPS
1.54%
7.58%
大文字化:
|
ボリューム (24 時間):